ArcticZymes Technologies Strengthens Board with Appointment of Dr. Hanna Pirita Lesch, Supporting Diversification into RNA and Continued Leadership in Cell & Gene Therapy

▤ Summary

ArcticZymes Technologies appointed Dr. Hanna Pirita Lesch to its Board of Directors after approval at its Annual General Meeting. The company also re-elected Dr. Frank Mathias as Chair and Petter Dragesund as a board member, while Sharon Brownlow stepped down. ArcticZymes said the appointment supports its strategy to expand into RNA with a dedicated enzyme portfolio and to keep strengthening its cell and gene therapy position. The company highlighted Dr. Lesch’s experience in RNA, viral vector manufacturing, and advanced therapy programs as directly relevant to its next growth phase.

▦ Linked Companies